verified SJR 1,04 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Wolters Kluwer Health

workspace_premium Q1 — Infectious Diseases lock Subscription

Journal of Acquired Immune Deficiency Syndromes

Journal of Acquired Immune Deficiency Syndromes is a journal indexed in SJR in Infectious Diseases and Pharmacology (medical) with an H index of 176. It has an SJR impact factor of 1,04 and it has a best quartile of Q1. It has an SJR impact factor of 1,04.

Journal of Acquired Immune Deficiency Syndromes focuses its scope in these topics and keywords: hiv, health, viral, expression, antiretroviral, therapy, women, cd, infant, public, ...

ISSN: 1525-4135

Publisher: Wolters Kluwer Health

Category: Infectious Diseases

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,04 Q1

H-index 176

Acceptance rate pie_chart

21% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,04

H-index

176

Docs (year)

233

Docs 3y

785

Total refs

8630

Cites 3y

1988

Citable 3y

725

Cites/Doc 2y

2.08

Ref/Doc

37.04

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men

What HIV Programs Work for Adolescent Girls?

Comparison of Generic Zidovudine + Lamivudine (Cipla, Duovir) and the GlaxoSmithKline Brand (Combivir) Tablets

Clinical Utility of Resistance Testing: Retrospective and Prospective Data Supporting Use and Current Recommendations

Clinical Impact of HTLV-1 Infection in Spain: Implications for Public Health and Mandatory Screening

Clarification

Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte-Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group

Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders

Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir

Can HIV-Infected Patients Fast During the Month of Ramadan?

C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection

Brief Report

SHOW MORE ARTICLES

Brief Report

129 Human Endogenous Retrovirus-K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer

Bacterial and Mycobacterial Meningitis in HIV-Positive Compared with HIV-Negative Patients in an Internal Medicine Ward in Libreville, Gabon

Antibodies From HIV-Positive and AIDS Patients Bind to an HIV Envelope Multivalent Vaccine

An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda

An Exploratory Study of Correlates of Allostatic Load in Older People Living With HIV

Adequacy of Prenatal Care and Prescription of Zidovudine to Prevent Perinatal HIV Transmission

Addressing Poor Retention of Infants Exposed to HIV

Addition of Single-Dose Tenofovir and Emtricitabine to Intrapartum Nevirapine to Reduce Perinatal HIV Transmission

A Study Comparing Sexually Transmitted Infections and HIV Among Ex-Red-Light District and Non-Red-Light District Sex Workers After the Demolition of Baina Red-Light District

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

A Prognostic Model for HIV Seroconversion Among Injection Drug Users as a Tool for Stratification in Clinical Trials

FAQs

Journal of Acquired Immune Deficiency Syndromes has an SJR of 1,04 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD). Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Journal of Acquired Immune Deficiency Syndromes is 21%.

Journal of Acquired Immune Deficiency Syndromes

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Journal of Acquired Immune Deficiency Syndromes?

What is the APC / publication cost?

What is the acceptance rate?